Local and national advocacy support

Ralph S. Shapiro, Marcia Boyle, Elena E. Perez

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient's experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies.

Original languageEnglish (US)
Pages (from-to)S423-S426
JournalJournal of Clinical Immunology
Issue numberSUPPL. 2
StatePublished - 2012


  • AAAAI IGIV toolkit
  • Immune Deficiency Foundation
  • Jeffrey Modell Foundation
  • Primary immunodeficiency disease
  • Treatment guidelines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Local and national advocacy support'. Together they form a unique fingerprint.

Cite this